AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37933185 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1525
Study 37933185 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth platform
Number of subjects: 1525
Study 37933187 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 870
Study 37933187 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 870
Study 37933196 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37933546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (survey administered)
Number of subjects: 72
Study 37933546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no survey administered)
Number of subjects: 72
Study 37933882 — intervention group
Group type: EXPERIMENTAL
Intervention: AREN0533
Number of subjects: 148
Study 37933882 — intervention group
Group type: COMPARATOR
Intervention: NWTS-5
Number of subjects: 148
Study 37933882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled cohort
Number of subjects: 148
Study 37933898 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser efficiency with Laryngeal Mask Airway (LMA)
Number of subjects: 0
Study 37933898 — intervention group
Group type: COMPARATOR
Intervention: Holmium laser efficiency with Endotracheal Intubation (ETI)
Number of subjects: 0
Study 37933978 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry-based motivational intervention (IG)
Number of subjects: 614
Study 37933978 — intervention group
Group type: COMPARATOR
Intervention: Brief smoking cessation counselling (CG)
Number of subjects: 614
Study 37934000 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy under investigation in basket trials
Number of subjects: 0
Study 37934289 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 0
Study 37934289 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study 37934301 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloidotherapy (15 sessions for 3 weeks, 5 days a week)
Number of subjects: 90
Study 37934301 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) (3 sessions for 3 weeks, once a week, 1.8 bar, 10.0 Hz, 2000 impulses)
Number of subjects: 90
Study 37934400 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized mat-Pilates sessions (45 min, twice weekly)
Number of subjects: 63
Study 37934400 — intervention group
Group type: COMPARATOR
Intervention: Home-based general exercise program (Control Group)
Number of subjects: 63
Study 37934530 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty TUD services (including behavioral counseling and medications for tobacco treatment)
Number of subjects: 18
Study 37934530 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 18
Study 37934561 — intervention group
Group type: EXPERIMENTAL
Intervention: SALIENCE training (30 minutes, 3 times a week for 2 weeks, total of 6 sessions)
Number of subjects: 62
Study 37934561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SALIENCE training)
Number of subjects: 62
Study 37934566 — intervention group
Group type: EXPERIMENTAL
Intervention: DWELL intervention (Facebook group providing practical solutions for home design for wellness)
Number of subjects: 643
Study 37934566 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist, no intervention)
Number of subjects: 643
Study 37934572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system for personalized pain management recommendations
Number of subjects: 0
Study 37934573 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 175
Study 37934573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 37934611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738) 160 mg twice daily for 2 weeks in a 4-weekly cycle
Number of subjects: 67
Study 37934611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738) at doses of 20-240 mg BD continuously or intermittently
Number of subjects: 67
Study 37934611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738)
Number of subjects: 67
Study 37934880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 10
Study 37934948 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 4595
Study 37934948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4595
Study 37935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (≤20 ng/mL)
Number of subjects: 1191
Study 37935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for age and paclitaxel schedule
Number of subjects: 1191
Study 37935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-deficient diet in mice
Number of subjects: 1191
Study 37935133 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term MBT (5 months)
Number of subjects: 166
Study 37935133 — intervention group
Group type: COMPARATOR
Intervention: Long-term MBT (14 months)
Number of subjects: 166
Study 37935200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 66
Study 37935200 — intervention group
Group type: EXPERIMENTAL
Intervention: Water fasting (WF)
Number of subjects: 66
Study 37935200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 37935304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed $100 incentive
Number of subjects: 330
Study 37935304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed $200 incentive
Number of subjects: 330
Study 37935304 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed $100 incentive
Number of subjects: 330
Study 37935304 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed $200 incentive
Number of subjects: 330
Study 37935304 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 330
Study 37935304 — intervention group
Group type: EXPERIMENTAL
Intervention: All incentive groups
Number of subjects: 330
Study 37935416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively stimulating semistructured conversations via internet/webcam 4 times per week for 6 months, then twice per week for an additional 6 months; plus weekly 10 minutes telephone check-ins
Number of subjects: 186
Study 37935416 — intervention group
Group type: COMPARATOR
Intervention: Weekly 10 minutes telephone check-ins
Number of subjects: 186
Study 37935475 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) psychotherapy
Number of subjects: 28
Study 37935475 — intervention group
Group type: COMPARATOR
Intervention: Health education (active control)
Number of subjects: 28
Study 37935477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 4 weeks
Number of subjects: 0
Study 37935477 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 37935524 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib alone after carboplatin/paclitaxel
Number of subjects: 970
Study 37935524 — intervention group
Group type: COMPARATOR
Intervention: Niraparib in combination with bevacizumab after carboplatin/paclitaxel
Number of subjects: 970
Study 37935531 — intervention group
Group type: COMPARATOR
Intervention: MFG (family-strengthening intervention)
Number of subjects: 89
Study 37935531 — intervention group
Group type: COMPARATOR
Intervention: G-CBT (group-cognitive behavioral therapy)
Number of subjects: 89
Study 37935531 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 89
Study 37935564 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enriched TME subtype
Number of subjects: 271
Study 37935631 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib in combination with fulvestrant
Number of subjects: 2436
Study 37935631 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2436
Study 37935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion after 1-3 recanalization attempts
Number of subjects: 1078
Study 37935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion after 4 or more recanalization attempts
Number of subjects: 1078
Study 37935652 — intervention group
Group type: COMPARATOR
Intervention: Comparison with large vessel occlusions (LVO)
Number of subjects: 1078
Study 37935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 1078
Study 37935839 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born to mothers with PCOS
Number of subjects: 556
Study 37935839 — intervention group
Group type: COMPARATOR
Intervention: Children born to mothers without PCOS
Number of subjects: 556
Study 37935913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 21 after FET
Number of subjects: 178
Study 37935913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 28 after FET
Number of subjects: 178
Study 37935913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 14 after FET
Number of subjects: 178
Study 37935913 — intervention group
Group type: COMPARATOR
Intervention: Serum HCG on days 21 and 28
Number of subjects: 178
Study 37935977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin and cytarabine (DA)
Number of subjects: 738
Study 37935977 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin with higher dose cytarabine (IA)
Number of subjects: 738
Study 37935977 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin with higher dose cytarabine and vorinostat (IA+V)
Number of subjects: 738
Study 37935977 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable cytogenetics subset with DA
Number of subjects: 738
Study 37935977 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose cytarabine (with or without vorinostat)
Number of subjects: 738
Study 37935997 — intervention group
Group type: EXPERIMENTAL
Intervention: RPF group (n=95)
Number of subjects: 159
Study 37935997 — intervention group
Group type: EXPERIMENTAL
Intervention: RVF group (n=38)
Number of subjects: 159
Study 37935997 — intervention group
Group type: COMPARATOR
Intervention: RPF group
Number of subjects: 159
Study 37935997 — intervention group
Group type: COMPARATOR
Intervention: RVF group
Number of subjects: 159
Study 37935997 — intervention group
Group type: EXPERIMENTAL
Intervention: Male RPF group
Number of subjects: 159
Study 37935997 — intervention group
Group type: EXPERIMENTAL
Intervention: Female RPF group
Number of subjects: 159
Study 37936136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor capabilities (specifically stereognosis and barognosis)
Number of subjects: 27
Study 37936136 — intervention group
Group type: EXPERIMENTAL
Intervention: MTT measure of stereognosis
Number of subjects: 27
Study 37936136 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRS and MTT measure of barognosis
Number of subjects: 27
Study 37936136 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of drugs and duration of illness
Number of subjects: 27
Study 37936166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities
Number of subjects: 39
Study 37936166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 39
Study 37936218 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized telephone counseling
Number of subjects: 577
Study 37936218 — intervention group
Group type: COMPARATOR
Intervention: State Quitline referral
Number of subjects: 577
Study 37936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial therapeutic clothing (chitosan) + standard topical treatment
Number of subjects: 159
Study 37936331 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial therapeutic clothing (silver) + standard topical treatment
Number of subjects: 159
Study 37936331 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic clothing + standard topical treatment
Number of subjects: 159
Study 37936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist therapy
Number of subjects: 1043
Study 37936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Number of subjects: 1043
Study 37936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 1043
Study 37936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1043
Study 37936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill and stair climbing (from the COPD Assessment Test)
Number of subjects: 1043
Study 37936551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence support strategies including monthly counselling sessions with drug-level feedback (DLF), optional daily SMS reminders, weekly phone or SMS check-ins, peer support clubs, and additional counselling.
Number of subjects: 247
Study 37936551 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling sessions with DLF provided at 54.3% of sessions.
Number of subjects: 247
Study 37936551 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person clubs and weekly calls as support strategies.
Number of subjects: 247
Study 37936551 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative adherence support strategies.
Number of subjects: 247
Study 37936551 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation programmes offering a menu of support options.
Number of subjects: 247
Study 37936652 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (10 μg of the spike protein from the ancestral D614 strain)
Number of subjects: 10114
Study 37936652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10114
Study 37936652 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant
Number of subjects: 10114
Study 37936658 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 68
Study 37936658 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 68
Study 37936687 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1604 at 3 mg/kg Q2W
Number of subjects: 35
Study 37936687 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1604
Number of subjects: 35
Study 37936687 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1604 at 3 mg/kg (Q2W and Q3W) and 200 mg (Q3W)
Number of subjects: 35
Study 37936699 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell data
Number of subjects: 51
Study 37936699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RSV season T-cell phenotypes
Number of subjects: 51
Study 37936699 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological parameters evaluation
Number of subjects: 51
Study 37936786 — intervention group
Group type: EXPERIMENTAL
Intervention: Anplag® 90mg (Ticagrelor) tablet
Number of subjects: 0
Study 37936786 — intervention group
Group type: COMPARATOR
Intervention: Brilinta® 90 mg (Ticagrelor) tablet
Number of subjects: 0
Study 37937287 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct wire pacing (DWP) during FFR measurement
Number of subjects: 94
Study 37937287 — intervention group
Group type: COMPARATOR
Intervention: Standard method (without DWP)
Number of subjects: 94
Study 37937305 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 33
Study 37937305 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement evoked pain (MEP)
Number of subjects: 33
Study 37937322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue and Activity Management Education for Work (FAME-W) intervention
Number of subjects: 0
Study 37937322 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37937397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 37937397 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab or pembrolizumab alone
Number of subjects: 0
Study 37937444 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT)
Number of subjects: 0
Study 37937444 — intervention group
Group type: COMPARATOR
Intervention: Immunochemotherapy without radiotherapy (control group)
Number of subjects: 0
Study 37937645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus for 12 or more months
Number of subjects: 132
Study 37937645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus for 2 years
Number of subjects: 132
Study 37937645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 132
Study 37937645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus in PIK3CA-mutated patients
Number of subjects: 132
Study 37937763 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib-chemotherapy
Number of subjects: 557
Study 37937763 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 557
Study 37937777 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 117
Study 37937777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 37937851 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study 37937851 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI Withdrawal
Number of subjects: 0
Study 37937851 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI Initiation
Number of subjects: 0
Study 37937851 — intervention group
Group type: COMPARATOR
Intervention: Control (Non-PPI Users)
Number of subjects: 0
Study 37938055 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead (BL) concentration measured by inductively coupled plasma mass spectrometry, baseline concentration 4.35 μg/dL, increased 3.17-fold over follow-up (median: 2.03 years; range: 0.92-6.45 years).
Number of subjects: 234
Study 37938095 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR (anterior cruciate ligament reconstruction)
Number of subjects: 20
Study 37938095 — intervention group
Group type: COMPARATOR
Intervention: Control group (age, sex, and activity matched)
Number of subjects: 20
Study 37938137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total femur replacement after tumor resection
Number of subjects: 0
Study 37938431 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of childhood ALL and NHL
Number of subjects: 6511
Study 37938475 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 2261
Study 37938475 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalization
Number of subjects: 2261
Study 37938475 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 infection rate ratio during wave 1
Number of subjects: 2261
Study 37938475 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 hospitalization rate ratio during wave 1
Number of subjects: 2261
Study 37938475 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 infection rate ratio during wave 2
Number of subjects: 2261
Study 37938475 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 hospitalization rate ratio during wave 2
Number of subjects: 2261
Study 37938495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 8381
Study 37938495 — intervention group
Group type: COMPARATOR
Intervention: No ESA
Number of subjects: 8381
Study 37938560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (fast delivery)
Number of subjects: 20
Study 37938560 — intervention group
Group type: COMPARATOR
Intervention: Oral methylphenidate (slow delivery)
Number of subjects: 20
Study 37938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC) vaccines
Number of subjects: 35
Study 37938599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status (worst vaccination status)
Number of subjects: 0
Study 37938599 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, fatigue, and current anxiety
Number of subjects: 0
Study 37938599 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of disease
Number of subjects: 0
Study 37938599 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities and recent headaches
Number of subjects: 0
Study 37938844 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3731
Study 37938844 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity measures (METs, ability to climb 1 floor, level of regular physical activity)
Number of subjects: 3731
Study 37938844 — intervention group
Group type: COMPARATOR
Intervention: Clinical scores (RCRI, age)
Number of subjects: 3731
Study 37938854 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser epilation (LE)
Number of subjects: 302
Study 37938854 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 302
Study 37938871 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (ACT), 7 sessions of 45-60 min over 4 weeks
Number of subjects: 140
Study 37938871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 37938875 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic monitoring every 3 months
Number of subjects: 442
Study 37938875 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic monitoring every 6 months
Number of subjects: 442
Study 37938875 — intervention group
Group type: EXPERIMENTAL
Intervention: Online monitoring every 3 months
Number of subjects: 442
Study 37938875 — intervention group
Group type: EXPERIMENTAL
Intervention: Online monitoring every 6 months
Number of subjects: 442
Study 37938917 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Gain measurement
Number of subjects: 0
Study 37938917 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37939122 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-anti-CD45 radioimmunotherapy
Number of subjects: 25
Study 37939124 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Durvalumab
Number of subjects: 114
Study 37939124 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Durvalumab with Bevacizumab
Number of subjects: 114